Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4688 USD | +5.81% | +23.04% | +6.57% |
Mar. 20 | Transcript : AIM ImmunoTech Inc. - Special Call | |
Feb. 20 | AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding | CI |
Financials (USD)
Sales 2023 * | 157K | Sales 2024 * | 70K | Capitalization | 21.64M |
---|---|---|---|---|---|
Net income 2023 * | -22M | Net income 2024 * | -27M | EV / Sales 2023 * | 138 x |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 309 x |
P/E ratio 2023 * |
-0.98
x | P/E ratio 2024 * |
-0.98
x | Employees | 23 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 91.31% |
Latest transcript on AIM ImmunoTech Inc.
1 day | +0.91% | ||
1 week | +10.72% | ||
Current month | +10.47% | ||
1 month | +8.02% | ||
3 months | -10.18% | ||
6 months | -3.86% | ||
Current year | +0.70% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 72 | 08-11-16 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 22-04-03 |
Chief Tech/Sci/R&D Officer | - | 22-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 23-03-27 |
Chairman | 88 | 98-06-30 | |
Thomas Equels
CEO | Chief Executive Officer | 72 | 08-11-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.4688 | +5.81% | 80 564 |
24-03-27 | 0.443 | +0.91% | 172,286 |
24-03-26 | 0.439 | -0.23% | 231,694 |
24-03-25 | 0.44 | -0.83% | 931,165 |
24-03-22 | 0.4437 | +16.46% | 197,288 |
Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.70% | 21.64M | |
+2.56% | 108B | |
+10.02% | 104B | |
+6.99% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |